LONGEVA.

Ipamorelin reference dosing

ipamorelin dosage

> Updated:

Ipamorelin (preset)

Calculate the Ipamorelin dose

The calculator is already set up for Ipamorelin — adjust the dose or diluent volume for your vial.

Open calculator

In short

Ipamorelin is a pentapeptide that stimulates growth hormone release through ghrelin receptors. Its distinguishing feature is selectivity: it does not raise cortisol or ACTH beyond the level GHRH itself produces (Raun and colleagues, 1998). The schedule on this page: start at 100 mcg subcutaneously once daily as a tolerance assessment, titrate by 50 mcg every 1–2 weeks, main regimen 200–300 mcg per day split across 1–3 injections, often 30–60 minutes before sleep.

Human dosing

Ipamorelin dosing questions usually come down to injection frequency rather than a single dose: the table below shows how the starting dose is raised toward the main regimen.

Period / conditionDoseEscalation
Start (tolerance assessment)100 mcg subcutaneously, once dailyStarting dose
Gradual titration+50 mcg every 1–2 weeks as neededIncrease if needed
Main regimen200–300 mcg per day, split across 1–3 injectionsMaximum in this schedule
Practical dosing and effect details

Ipamorelin is a pentapeptide that stimulates growth hormone (GH) release through ghrelin receptors. Raun and colleagues (European Journal of Endocrinology, 1998) showed it produces strong GH-releasing activity while not raising cortisol or ACTH beyond the level GHRH itself produces; that selectivity is what set it apart from older GH secretagogues, which trigger a broader hormonal cascade.

That selectivity ties directly to the schedule on this page: because the peptide does not touch off parallel hormonal spikes, protocols split the dose into several small injections per day (1 to 3) rather than one large dose. The starting dose is labeled a tolerance assessment: GH secretagogues can cause injection-site flushing, and a small first dose lets that reaction be checked before moving to the main regimen. Dosing before sleep lines up with the body's own nightly GH pulse.

This is reference information on regimens from published sources, not a medical recommendation.

Frequently asked questions

What is ipamorelin used for? It is a pentapeptide secretagogue: it stimulates growth hormone release through ghrelin receptors. What sets it apart from older secretagogues is selectivity – it does not raise cortisol or ACTH beyond the level GHRH itself produces (Raun and colleagues, 1998).

Why is the daily dose split into 1–3 injections? Because ipamorelin does not trigger parallel hormonal spikes, protocols split the dose into several small injections per day instead of one large dose; the evening dose is often placed 30–60 minutes before sleep, in line with the body's own nightly GH pulse.

Does ipamorelin come as tablets or a spray? In the protocols compiled on this page, ipamorelin is used only as a subcutaneous injection; these sources do not describe tablet or spray forms.

What reaction does the starting dose check for? GH secretagogues can cause flushing at the injection site, so the first 100 mcg are labeled a tolerance assessment: the reaction is checked before moving to the main regimen.

How to reconstitute

An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.

  1. 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 5 mg vial.Ipamorelin5 mg+ 2 mlDiluent
  2. 2Get the concentrationExample: 5 mg in 2 ml =Ipamorelin2.5 mg/ml(2,500 mcg/ml)
  3. 3Work out the volume per doseFor example, for a 0.2 mg dose:0.2 mg = 0.08 ml= 8 u. (U-100)

This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →

Research protocols

Ipamorelin: reference regimens

Ipamorelin is used as a subcutaneous injection; this is a generalized reference compiled from published studies and common protocols. Single doses are typically given 1–3 times per day, often 30–60 min before sleep.

More scientific background in the Ipamorelin monograph

Notes and safety

  • • Ipamorelin is a research peptide. Human safety and efficacy data are limited.
  • • The regimens shown are based on publications and research protocols, not clinical recommendations.
  • • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
  • • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
  • • This information is for educational purposes and is not medical advice.
This is not medical advice — research information only.This material is not intended for diagnosis, treatment or prevention of disease.